The gastrointestinal disorder drug developer was co-founded by researchers from Stanford University.

Mozart Therapeutics, US-based autoimmune and inflammatory disease drug developer co-founded by Stanford University researchers, publicly launched yesterday with $55m in series A funding led by Arch Venture Partners. Pharmaceutical producers Bayer, Eli Lilly and Merck & Co all took part, as did Sofinnova Partners and Altitude Life Science Ventures as well as Alexandria Venture Investments,…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.